申请人:Eli Lilly and Company
公开号:US06303816B1
公开(公告)日:2001-10-16
Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula
R1—L—NHSO2R2 I
in which
R1 represents an unsubstituted or substituted aromatic or heteroaromatic group;
R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and
L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring;
and pharmaceutically acceptable salts thereof.
Also disclosed are compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.
在哺乳动物中,使用有效量的公式 I 所示化合物的谷氨酸受体功能可以被增强:R1—L—NHSO2R2 I 其中:R1 代表未取代或取代的芳香族或杂芳族基团;R2 代表 (1-6C) 烷基,(3-6C) 环烷基,(1-6C) 氟代烷基,(1-6C) 氯代烷基,(2-6C) 烯丙基,(1-4C) 烷氧基(1-4C) 烷基,未取代或被卤素、(1-4C) 烷基或(1-4C) 烷氧基取代的苯基,或者一个由 R3R4N 组成的基团,其中 R3 和 R4 各自独立地代表 (1-4C) 烷基,或者与它们所连接的氮原子一起形成一个氮杂环丁烷基、吡咯烷基、哌啶基、吗啡啉基、哌嗪基、六氢氮杂环庚基或八氢氮杂环辛基;L 代表一个未取代或取代有一个或两个独立选择的(1-6C) 烷基、芳基(1-6C) 烷基、(2-6C) 烯丙基、芳基(2-6C) 烯丙基和芳基的 (2-4C) 烷烯链,或者两个取代基,它们与它们所连接的碳原子或碳原子一起形成一个 (3-8C) 碳环烷基;以及它们的药物可接受的盐。还公开了公式 I 的化合物、它们的制备过程以及包含它们的药物组合物。